

**LOCAL RECURRENCE OF PROSTATE CANCER (rPCa)
TREATED BY FOCUSED ULTRASOUND (HIFU)**

S.Thuroff, Ch. Chaussy

Dep. of Urology, Munchen Harlaching, Germany

INTRODUCTION: rPCa after surgery, radiation or hormonal ablation has been an increasing problem because of poor therapeutic alternatives. A small tumor volume, visible in transrectal ultrasound (TRUS) and proven by biopsy can be treated locally by HIFU with a non invasive rectal approach. In a single session, HIFU is applied to the target tissue volume.

MATERIAL & METHOD: 28 patients with biopsy proven rPCa and PSA levels increasing were treated by transrectal HIFU (Ablatherm)* at 2.25 - 3.0 MHz and 50 Watt. 7 patients had radiation (R), 7 radical surgery (S) and 14 hormonal ablation (HA) as primary therapy. Tumor volumes were small (\emptyset : S = 4cc / R = 15cc / HA = 17cc). Initial Gleason score showed ≥ 7 in 50%. After a treatment time of 45 min patients were discharged from hospital within 23 hours. All patients had a suprapubic urinary tube (\emptyset 29 days). PSA, biopsies, IPS-, QLF- and complaint score were followed during 1,3,6,9,12,18 months.

RESULTS: Biopsies were negative in 78 % of the cases. After HIFU monotherapy no severe side effects were observed.

CONCLUSION: HIFU appears to be locally high effective in rPCa without severe side effects in monotherapy. Transrectal HIFU can be applied as "out patient procedure". If a secondary HIFU treatment is needed, side effect rate rises significantly.

(*EDAP-TMS, Lyon-France)